Header Logo

Connection

Joan Walker to Female

Back to Details
This is a "connection" page, showing publications Joan Walker has written about Female.
Joan Walker
Connection Strength
2.035
Female
  1. Reply to F. Tomao et al and E.A. De Jaeghere et al. J Clin Oncol. 2019 11 20; 37(33):3170.
    View in: PubMed
    Score: 0.053
  2. Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. J Clin Oncol. 2019 09 20; 37(27):2416-2419.
    View in: PubMed
    Score: 0.053
  3. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
    View in: PubMed
    Score: 0.052
  4. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol. 2018 01; 218(1):109.e1-109.e11.
    View in: PubMed
    Score: 0.046
  5. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2. Int J Gynecol Cancer. 2017 05; 27(4):730-737.
    View in: PubMed
    Score: 0.045
  6. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
    View in: PubMed
    Score: 0.043
  7. Intraperitoneal chemotherapy for ovarian cancer. Gynecol Oncol. 2016 07; 142(1):1-2.
    View in: PubMed
    Score: 0.042
  8. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015 Jul 01; 121(13):2108-20.
    View in: PubMed
    Score: 0.039
  9. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014 Apr; 133(1):23-7.
    View in: PubMed
    Score: 0.036
  10. Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients. Ann Oncol. 2013 Dec; 24 Suppl 10:x41-45.
    View in: PubMed
    Score: 0.036
  11. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jul; 130(1):12-8.
    View in: PubMed
    Score: 0.034
  12. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
    View in: PubMed
    Score: 0.033
  13. Tubal ligation frequency in Oklahoma women with cervical cancer. Gynecol Oncol. 2012 Nov; 127(2):278-82.
    View in: PubMed
    Score: 0.032
  14. Re: clinical practice guidelines for the management of patients with endometrial cancer in France. Int J Gynecol Cancer. 2012 Feb; 22(2):179-81.
    View in: PubMed
    Score: 0.031
  15. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.031
  16. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
    View in: PubMed
    Score: 0.031
  17. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar; 124(3):529-33.
    View in: PubMed
    Score: 0.031
  18. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31.
    View in: PubMed
    Score: 0.030
  19. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar; 120(3):459-63.
    View in: PubMed
    Score: 0.029
  20. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10; 27(32):5331-6.
    View in: PubMed
    Score: 0.027
  21. Role of laparoscopic surgery in the management of endometrial cancer. J Natl Compr Canc Netw. 2009 May; 7(5):559-67.
    View in: PubMed
    Score: 0.026
  22. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol. 2009 Mar; 112(3):439-40.
    View in: PubMed
    Score: 0.026
  23. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):113-20.
    View in: PubMed
    Score: 0.025
  24. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Jan; 112(1):78-84.
    View in: PubMed
    Score: 0.025
  25. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008 Feb; 108(2):342-7.
    View in: PubMed
    Score: 0.023
  26. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006 Aug; 195(2):341-8.
    View in: PubMed
    Score: 0.021
  27. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006 Feb 20; 24(6):988-94.
    View in: PubMed
    Score: 0.021
  28. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan; 100(1):27-32.
    View in: PubMed
    Score: 0.021
  29. Can frequency and severity of symptoms predict the presence of ovarian cancer? Nat Clin Pract Oncol. 2004 Dec; 1(2):72-3.
    View in: PubMed
    Score: 0.019
  30. Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy. Obstet Gynecol. 2025 Jan 01; 145(1):21-30.
    View in: PubMed
    Score: 0.019
  31. High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancer. J Natl Compr Canc Netw. 2004 Nov; 2(6):589-96.
    View in: PubMed
    Score: 0.019
  32. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
    View in: PubMed
    Score: 0.018
  33. Management of atypical and low-grade cervical cytology. Cancer J. 2003 Sep-Oct; 9(5):377-81.
    View in: PubMed
    Score: 0.017
  34. Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Lancet Gastroenterol Hepatol. 2023 10; 8(10):908-918.
    View in: PubMed
    Score: 0.017
  35. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 Dec 01; 40(34):3965-3974.
    View in: PubMed
    Score: 0.016
  36. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.016
  37. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol. 2022 02 01; 139(2):157-162.
    View in: PubMed
    Score: 0.016
  38. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
    View in: PubMed
    Score: 0.016
  39. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.
    View in: PubMed
    Score: 0.015
  40. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021 11; 163(2):392-397.
    View in: PubMed
    Score: 0.015
  41. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
    View in: PubMed
    Score: 0.015
  42. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
    View in: PubMed
    Score: 0.015
  43. Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers. Gynecol Oncol. 2021 02; 160(2):625-632.
    View in: PubMed
    Score: 0.014
  44. GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol. 2021 01; 160(1):244-251.
    View in: PubMed
    Score: 0.014
  45. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 01; 156(1):131-139.
    View in: PubMed
    Score: 0.013
  46. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.013
  47. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
    View in: PubMed
    Score: 0.013
  48. GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE). Gynecol Oncol. 2019 12; 155(3):452-460.
    View in: PubMed
    Score: 0.013
  49. Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Gynecol Oncol. 1998 Dec; 71(3):458-60.
    View in: PubMed
    Score: 0.013
  50. Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. Cancer Cytopathol. 2018 11; 126(11):950-958.
    View in: PubMed
    Score: 0.012
  51. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 11; 151(2):257-263.
    View in: PubMed
    Score: 0.012
  52. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol. 2018 11; 219(5):459.e1-459.e11.
    View in: PubMed
    Score: 0.012
  53. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
    View in: PubMed
    Score: 0.012
  54. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 07; 150(1):119-126.
    View in: PubMed
    Score: 0.012
  55. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.011
  56. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145.
    View in: PubMed
    Score: 0.011
  57. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.011
  58. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
    View in: PubMed
    Score: 0.011
  59. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.011
  60. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
    View in: PubMed
    Score: 0.011
  61. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.011
  62. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.
    View in: PubMed
    Score: 0.011
  63. Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clin Cancer Res. 2017 04 15; 23(8):1955-1966.
    View in: PubMed
    Score: 0.011
  64. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 07 01; 34(19):2279-86.
    View in: PubMed
    Score: 0.011
  65. Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. J Low Genit Tract Dis. 2016 Apr; 20(2):154-61.
    View in: PubMed
    Score: 0.010
  66. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016 Feb 25; 374(8):738-48.
    View in: PubMed
    Score: 0.010
  67. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32.
    View in: PubMed
    Score: 0.010
  68. Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:143-51.
    View in: PubMed
    Score: 0.010
  69. Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis. 2016 Feb; 37(2):188-196.
    View in: PubMed
    Score: 0.010
  70. Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis. 2015 Nov 25; 15:544.
    View in: PubMed
    Score: 0.010
  71. Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecol Oncol. 2015 Oct; 139(1):70-6.
    View in: PubMed
    Score: 0.010
  72. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol. 2015 Oct; 139(1):17-22.
    View in: PubMed
    Score: 0.010
  73. Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecol Oncol. 2015 Sep; 138(3):712-6.
    View in: PubMed
    Score: 0.010
  74. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.010
  75. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.
    View in: PubMed
    Score: 0.010
  76. Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. Gynecol Oncol. 2015 Jul; 138(1):101-8.
    View in: PubMed
    Score: 0.010
  77. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015 Jan 01; 33(1):83-9.
    View in: PubMed
    Score: 0.010
  78. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
    View in: PubMed
    Score: 0.009
  79. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
    View in: PubMed
    Score: 0.009
  80. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
    View in: PubMed
    Score: 0.009
  81. Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. Cancer Cytopathol. 2014 Sep; 122(9):694-701.
    View in: PubMed
    Score: 0.009
  82. Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. J Clin Virol. 2014 Aug; 60(4):414-7.
    View in: PubMed
    Score: 0.009
  83. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7.
    View in: PubMed
    Score: 0.009
  84. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Mar; 132(3):585-92.
    View in: PubMed
    Score: 0.009
  85. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
    View in: PubMed
    Score: 0.009
  86. Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic. J Clin Microbiol. 2014 Jan; 52(1):187-92.
    View in: PubMed
    Score: 0.009
  87. Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study. Int J Cancer. 2014 Jan 15; 134(2):411-25.
    View in: PubMed
    Score: 0.009
  88. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
    View in: PubMed
    Score: 0.008
  89. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
    View in: PubMed
    Score: 0.008
  90. Comparison of clinical versus surgical staging systems in vulvar cancer. Obstet Gynecol. 1992 Dec; 80(6):927-30.
    View in: PubMed
    Score: 0.008
  91. Hypogastric artery aneurysm masquerading as an ovarian neoplasm. Gynecol Oncol. 1992 Dec; 47(3):382-4.
    View in: PubMed
    Score: 0.008
  92. Reproducibility of linear array for human papillomavirus genotyping. J Clin Microbiol. 2013 Feb; 51(2):625-8.
    View in: PubMed
    Score: 0.008
  93. Sexual function of patients with endometrial cancer enrolled in the Gynecologic Oncology Group LAP2 Study. Int J Gynecol Cancer. 2012 Nov; 22(9):1624-33.
    View in: PubMed
    Score: 0.008
  94. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. Cancer Causes Control. 2012 Dec; 23(12):2013-21.
    View in: PubMed
    Score: 0.008
  95. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50.
    View in: PubMed
    Score: 0.008
  96. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012 Aug 01; 18(15):4154-62.
    View in: PubMed
    Score: 0.008
  97. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):367-71.
    View in: PubMed
    Score: 0.008
  98. Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens. J Clin Microbiol. 2012 May; 50(5):1564-70.
    View in: PubMed
    Score: 0.008
  99. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):286-92.
    View in: PubMed
    Score: 0.008
  100. Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS One. 2012; 7(1):e29051.
    View in: PubMed
    Score: 0.008
  101. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
    View in: PubMed
    Score: 0.008
  102. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma? Gynecol Oncol. 2012 Apr; 125(1):94-8.
    View in: PubMed
    Score: 0.008
  103. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Feb; 120(2):224-8.
    View in: PubMed
    Score: 0.007
  104. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
    View in: PubMed
    Score: 0.007
  105. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8.
    View in: PubMed
    Score: 0.007
  106. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer. 2009 Nov 15; 125(10):2434-40.
    View in: PubMed
    Score: 0.007
  107. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Nov 10; 27(32):5337-42.
    View in: PubMed
    Score: 0.007
  108. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.006
  109. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol. 2009 Feb; 112(2):337-41.
    View in: PubMed
    Score: 0.006
  110. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Jan; 112(1):134-41.
    View in: PubMed
    Score: 0.006
  111. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008 Jun 01; 26(16):2674-82.
    View in: PubMed
    Score: 0.006
  112. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.006
  113. Cervical dysplasia among women over 35 years of age. Am J Obstet Gynecol. 2008 Nov; 199(5):471.e1-5.
    View in: PubMed
    Score: 0.006
  114. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jul; 110(1):76-82.
    View in: PubMed
    Score: 0.006
  115. Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jul; 110(1):60-4.
    View in: PubMed
    Score: 0.006
  116. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71.
    View in: PubMed
    Score: 0.006
  117. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol. 2008 Mar; 108(3):584-90.
    View in: PubMed
    Score: 0.006
  118. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007 Nov; 197(5):503.e1-6.
    View in: PubMed
    Score: 0.006
  119. Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. Gynecol Oncol. 2007 Sep; 106(3):572-8.
    View in: PubMed
    Score: 0.006
  120. Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer. 2007 Jun 15; 109(12):2454-60.
    View in: PubMed
    Score: 0.006
  121. Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. Gynecol Oncol. 2007 Sep; 106(3):521-5.
    View in: PubMed
    Score: 0.006
  122. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer. 2007 Feb 15; 109(4):645-9.
    View in: PubMed
    Score: 0.006
  123. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 01; 25(4):437-43.
    View in: PubMed
    Score: 0.006
  124. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006 Dec; 103(3):1038-42.
    View in: PubMed
    Score: 0.005
  125. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep; 102(3):432-9.
    View in: PubMed
    Score: 0.005
  126. Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone. Gynecol Oncol. 2006 Feb; 100(2):379-84.
    View in: PubMed
    Score: 0.005
  127. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05; 354(1):34-43.
    View in: PubMed
    Score: 0.005
  128. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer. 2005 Dec 20; 117(6):1007-12.
    View in: PubMed
    Score: 0.005
  129. Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods. Cancer Epidemiol Biomarkers Prev. 2005 Nov; 14(11 Pt 1):2665-8.
    View in: PubMed
    Score: 0.005
  130. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006 Jan; 100(1):128-32.
    View in: PubMed
    Score: 0.005
  131. Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns. Diagn Mol Pathol. 2005 Jun; 14(2):59-64.
    View in: PubMed
    Score: 0.005
  132. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.005
  133. Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol. 2004 Aug; 94(2):249-55.
    View in: PubMed
    Score: 0.005
  134. Endometrial cancer metastatic to infrarenal aortic lymph nodes unrecognized during laparoscopic inframesenteric aortic lymph node dissection. Gynecol Oncol. 2004 Apr; 93(1):260-2.
    View in: PubMed
    Score: 0.005
  135. Ligation of an anatomic variant of renal vasculature during laparoscopic periaortic lymph node dissection: a cause of postoperative renal infarction. Gynecol Oncol. 2003 Nov; 91(2):416-20.
    View in: PubMed
    Score: 0.004
  136. Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer. 2003 Nov 01; 98(9 Suppl):2044-51.
    View in: PubMed
    Score: 0.004
  137. Outpatient implantation of a central venous access system in gynecologic oncology patients. J Reprod Med. 2003 Nov; 48(11):875-81.
    View in: PubMed
    Score: 0.004
  138. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003 Aug; 90(2):325-30.
    View in: PubMed
    Score: 0.004
  139. Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol. 2003 Apr; 26(2):171-3.
    View in: PubMed
    Score: 0.004
  140. Laparoscopic pelvic and paraaortic lymph node dissection in the obese. Gynecol Oncol. 2002 Mar; 84(3):426-30.
    View in: PubMed
    Score: 0.004
  141. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22.
    View in: PubMed
    Score: 0.004
  142. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol. 2002 Jan; 22(1):23-7.
    View in: PubMed
    Score: 0.004
  143. Surgical management of early-stage endometrial cancer in the elderly: is laparoscopy feasible? Gynecol Oncol. 2001 Dec; 83(3):563-8.
    View in: PubMed
    Score: 0.004
  144. Laparoscopic pelvic and paraaortic lymph node dissection: analysis of the first 100 cases. Gynecol Oncol. 2001 Sep; 82(3):498-503.
    View in: PubMed
    Score: 0.004
  145. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.004
  146. Cost analysis of laparoscopy versus laparotomy for early endometrial cancer. Gynecol Oncol. 1999 Dec; 75(3):460-3.
    View in: PubMed
    Score: 0.003
  147. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9.
    View in: PubMed
    Score: 0.003
  148. Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Gynecol Oncol. 1996 May; 61(2):282-6.
    View in: PubMed
    Score: 0.003
  149. Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Gynecol Oncol. 1995 Dec; 59(3):376-8.
    View in: PubMed
    Score: 0.003
  150. Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. J Am Coll Surg. 1995 Jul; 181(1):72-4.
    View in: PubMed
    Score: 0.002
  151. Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients. J Am Coll Surg. 1994 Nov; 179(5):558-60.
    View in: PubMed
    Score: 0.002
  152. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994 Jan 15; 73(2):370-6.
    View in: PubMed
    Score: 0.002
  153. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990 Jun; 75(6):1016-22.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.